US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,832.93

+54.241.95%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:2,848.64

Open:2,778.70

Low:2,778.70

Close:2,778.69

Volume:2.37M

Turnover:50.51M

Market Cap:45.28B

Float Cap:42.29B

Loading ...

Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA

Simply Wall St.

MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing

THOMSON REUTERS

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate

Simply Wall St.

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

Femasys announces FDA approval of FemBloc modular premarket approval application

Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome

MT Newswires Live

Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device

Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States

THOMSON REUTERS

Femasys - Fembloc Approved for Marketing in Europe and Select International Markets

THOMSON REUTERS

Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding

DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List

THOMSON REUTERS

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares

Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share

Teva price target raised to $42 from $40 at Barclays

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)

Femasys Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Evofem Q2 FY26 Net Loss Widens to $8.55 Million; Net Product Sales Fall 45% to $2.63 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2832.933,"timestamp":1787673659230,"preClose":2778.6934,"halted":0,"volume":2368028,"delay":0,"changeRate":0.01952,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":54.239746,"latestTime":"08-25 12:01:00 EDT","open":2778.704,"high":2848.6401,"low":2778.704,"amount":50509003.999732,"amplitude":0.025169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.821577,"peRate":71.768844,"turnoverRate":0.001648,"increases":4,"decrements":1,"flats":0,"marketCap":45283693068,"floatMarketCap":42287842423},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2848.6401,"amplitude":0.025169,"preClose":2778.6934,"low":2778.704,"pbRate":"5.821577","latestPrice":2832.933,"volume":2367928,"delay":0,"open":2778.704,"prevYearClose":2379.9924,"prevWeekClose":2809.5261,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2752.8147,"twentyDayClose":2390.8718,"sixtyDayClose":2639.9878,"secType":"PLATE","market":"US","turnoverRate":0.001648,"peRate":71.768844,"marketCap":45283693068,"floatMarketCap":42287842423,"timestamp":1787673658073,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662724732","title":"Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2662724732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662724732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662519,"startTime":"0","endTime":"0","summary":"Daré Bio CEO flags Ovaprene interim Phase 3 results as potential catalyst in investor interviewDaré Bioscience management outlined its shift from development-stage to commercial-stage in a Virtual Inv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL4Scn4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BCDF","IE00BQXX3C00.GBP","NDAQ","BK4584","DARE","IE00BQXX3D17.EUR","SG9999014013.SGD","LU2095319765.USD","BK4112","BK4585","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4007","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","SG9999014021.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","03160","BK4585","HYLG","IDNA","BK4588","GDOC","BK4555","BK4584","DARE","BK4099","BK4604","MEDX","LABU","BK4007","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662581730","title":"Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662581730","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662581730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:28","pubTimestamp":1787660886,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status.\nSee our latest analysis for Teva Pharmaceutical Industries.\nThe ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4559","BK4596","LU2324357040.USD","BK4566","LU1983299246.USD","BK4584","TEVA","LABU","BK4585","BK4557","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661529765","title":"MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661529765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661529765?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:07","pubTimestamp":1787342833,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4139","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660633238","title":"Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660633238","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660633238?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232636,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) announced that the U.S. FDA has accepted its New Drug Application for ecopipam for pediatric Tourette syndrome with Priority Review status.\nEcopipam is described by Teva as a first in class therapy candidate targeting children and adolescents with Tourette syndrome, an area where no new treatments have been approved in over a decade.\nThe filing is backed by positive late stage clinical trial data and adds another potential branded medicine to Teva's...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4566","TEVA","LABU","LU1983299246.USD","LU2324357040.USD","BK4588","BK4585","BK4596","BK4007","BK4559","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660077421","title":"TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660077421","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660077421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:16","pubTimestamp":1787152563,"startTime":"0","endTime":"0","summary":"Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4559","BK4557","BK4588","LU2324357040.USD","BK4585","TEVA","BK4596","BK4584","LU1983299246.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","IDNA","PSCH","RSPH","TBXU","BMED","BK4082","XLVX","BK4584","MRNX","BBP","PINK","FEMY","IEIH","SYNB","TECB","BK4588","LFSC","MRNY","GDOC","BK4585","GNMX","LABU","BK4539","IYH","FRTY","IBB","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660624425","title":"Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2660624425","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660624425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:10","pubTimestamp":1787145009,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.The regulator has set a target action date for late in Q1 of 2027, the company said.The application is supported by phase 2b and phase 3 data, which showed a reduction in tic severity and sustained efficacy, Teva said.Teva Pharmaceutical Industries shares were up 1.8% in premarket activity Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TEVA","LABU","BK4596","BK4566","BK4559","BK4584","BK4585","LU1983299246.USD","BK4007","LU2324357040.USD","BK4557","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425838","title":"Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425838","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425838?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144434,"startTime":"0","endTime":"0","summary":"Femasys says FDA OKs modular PMA pathway for FemBloc birth control deviceFDA cleared Femasys to use a modular PMA submission pathway for FemBloc, its investigational non-surgical permanent birth contr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL8HTqC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BCDF","BK4584","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3D17.EUR","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4539","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BQXX3F31.USD","BK4588","BK4082","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660803425","title":"Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2660803425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660803425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4539","BK4082","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542580","title":"Femasys - Fembloc Approved for Marketing in Europe and Select International Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542580?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4539","BK4584","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646700","title":"Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660646700?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:04","pubTimestamp":1787058290,"startTime":"0","endTime":"0","summary":"Daré Bioscience DARE-HPV program advances with non-dilutive US government fundingDaré Bioscience said its DARE-HPV program for persistent high-risk HPV is advancing with non-dilutive government fundin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL9RX6Np:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","DARE","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4588","BK4584","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4007","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","BCDF","LU0314104364.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467776","title":"DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467776?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUA3YN9JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460749","title":"DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460749?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":"National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovationSAN DIEGO, Aug.  18, 2026 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346918/30757/en/dar%C3%A9-bioscience-ceo-sabrina-martucci-johnson-named-to-forbes-2026-50-over-50-innovation-list.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAR","LU1721429741.USD","BK4189","LU2211817866.USD","BK4584","LU2308191902.HKD","DARE","LU0630314457.HKD","LU0012050646.USD","FXG","BK4588","BK4007","LU2380233275.USD","LU0106261612.USD","BK4585","LABU","LU0345780950.USD","LU0345781412.USD","LU1803068623.USD","LU0256331488.USD","LU1721429402.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432587","title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432587","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432587?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:26","pubTimestamp":1786998405,"startTime":"0","endTime":"0","summary":"Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common sharesVeru: Chief Scientific Officer K Gary Barnette bought 1,800 common shares at USD 2.69 each.Directly owned common shares r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8W9cTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4584","BK4007","BK4183","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660820480","title":"Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2660820480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660820480?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:36","pubTimestamp":1786970176,"startTime":"0","endTime":"0","summary":"Daré Bioscience prices USD 6 million registered direct offering at USD 1.37 per shareDaré Bioscience priced a registered direct offering of 4,379,581 common shares, or pre-funded warrants, at USD 1.37","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9P7kcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660655484","title":"Teva price target raised to $42 from $40 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2660655484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660655484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:59","pubTimestamp":1786964399,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Teva (TEVA) to $42 from $40 and keeps an Overweight rating on the shares post the Q2 report. The firm se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-42-from-40-at-barclays-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-42-from-40-at-barclays-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4585","BK4596","BK4566","BK4588","LU2324357040.USD","TEVA","BK4559","BK4557","BK4007","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659827176","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659827176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659827176?lang=en_us&edition=fundamental","pubTime":"2026-08-16 02:30","pubTimestamp":1786818607,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DAR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-and-dare-bioscience-dare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-and-dare-bioscience-dare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLTE","BK4007","XBI","SAPH","BK4588","BK4581","HCSG","BK4584","APIE","ARMH","BK4585","LU0128526141.USD","DINT","LU0029874061.USD","DIVL","LABU","XLV","CVY","DARE","AADR","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135121","title":"Femasys Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135121","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:59","pubTimestamp":1786741167,"startTime":"0","endTime":"0","summary":"Femasys Inc reports results for the quarter ended June 30 - Earnings SummaryFemasys IncFEMY.OQreported a quarterly adjusted loss of $1.55 per share for the quarter ended June 30, higher than the same ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","FEMY","BK4539","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129844","title":"Evofem Q2 FY26 Net Loss Widens to $8.55 Million; Net Product Sales Fall 45% to $2.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129844","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129844?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:13","pubTimestamp":1786738420,"startTime":"0","endTime":"0","summary":"Evofem Q2 FY26 net loss widens to $8.55 million; net product sales fall 45% to $2.63 millionEvofem posted Q2 net product sales of $2.63 million, down 45% year over year.Cost of goods sold fell 32% to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL24jwrp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}